known to prolong QT interval; if a drug known to prolong QT interval must be used, more frequent ECG monitoring is recommended.vemurafenibvemurafenib and risperidone both increase QTc interval. Avoid or Use Alternate Drug. Concomitant use of vemurafenib with drugs that prolong QT interval is not recommended.vilanterol/fluticasone furoate inhaledrisperidone increases toxicity of vilanterol/fluticasone furoate inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.Monitor Closely (422)abirateroneabiraterone increases levels of risperidone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Avoid coadministration of abiraterone with substrates of CYP2D6. If alternative therapy cannot be used, exercise caution and consider a dose reduction of the CYP2D6 substrate.abobotulinumtoxinAabobotulinumtoxinA increases effects of risperidone by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects.acarboserisperidone, acarbose. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.aclidiniumaclidinium decreases levels of risperidone by pharmacodynamic antagonism. Use Caution/Monitor.risperidone increases effects of aclidinium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.acrivastineacrivastine and risperidone both increase sedation. Use Caution/Monitor.albiglutiderisperidone, albiglutide. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.albuterolrisperidone increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.albuterol and risperidone both increase QTc interval. Use Caution/Monitor.alfentanilalfentanil and risperidone both increase sedation. Use Caution/Monitor.alfuzosinrisperidone and alfuzosin both increase QTc interval. Use Caution/Monitor.alfuzosin and risperidone both increase QTc interval. Use Caution/Monitor.almotriptanalmotriptan, risperidone. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).alprazolamalprazolam and risperidone both increase sedation. Use Caution/Monitor.amifostineamifostine, risperidone. Either increases effects of the other by anti-hypertensive channel blocking. Use Caution/Monitor. Due to its alpha adrenergic antagonism, atypical antipsychotic agents has the potential to enhance the effect of certain antihypertensive agents. Monitor blood pressure and adjust dose accordingly.amiodaroneamiodarone will increase the level or effect of risperidone by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.amitriptylineamitriptyline and risperidone both increase QTc interval. Modify Therapy/Monitor Closely.risperidone and amitriptyline both increase sedation. Use Caution/Monitor.amobarbitalamobarbital and risperidone both increase sedation. Use Caution/Monitor.amoxapineamoxapine and risperidone both increase QTc interval. Modify Therapy/Monitor Closely.risperidone and amoxapine both increase sedation. Use Caution/Monitor.anticholinergic/sedative combosanticholinergic/sedative combos decreases levels of risperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.anticholinergic/sedative combos decreases levels of risperidone by pharmacodynamic antagonism. Use Caution/Monitor.risperidone increases effects of anticholinergic/sedative combos by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.apomorphinerisperidone and apomorphine both increase sedation. Use Caution/Monitor.apomorphine and risperidone both increase QTc interval. Use Caution/Monitor.arformoterolrisperidone increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.arformoterol and risperidone both increase QTc interval. Use Caution/Monitor.aripiprazolearipiprazole and risperidone both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.aripiprazole and risperidone both increase sedation. Use Caution/Monitor.aripiprazole and risperidone both increase QTc interval. Use Caution/Monitor.armodafinilrisperidone increases and armodafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.arsenic trioxidearsenic trioxide and risperidone both increase QTc interval. Use Caution/Monitor.artemether/lumefantrineartemether/lumefantrine will increase the level or effect of risperidone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.artemether/lumefantrine and risperidone both increase QTc interval. Modify Therapy/Monitor Closely.asenapineasenapine and risperidone both increase sedation. Use Caution/Monitor.asenapine transdermalasenapine transdermal and risperidone both increase sedation. Use Caution/Monitor.atogepantrisperidone will increase the level or effect of atogepant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.atomoxetineatomoxetine and risperidone both increase QTc interval. Use Caution/Monitor.atorvastatinatorvastatin will increase the level or effect of risperidone by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.atracuriumatracurium decreases levels of risperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.atracurium decreases levels of risperidone by pharmacodynamic antagonism. Use Caution/Monitor.risperidone increases effects of atracurium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.atropineatropine decreases levels of risperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.atropine decreases levels of risperidone by pharmacodynamic antagonism. Use Caution/Monitor.risperidone increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.atropine IV/IMrisperidone increases effects of atropine IV/IM by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.atropine IV/IM decreases levels of risperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.atropine IV/IM decreases levels of risperidone by pharmacodynamic antagonism. Use Caution/Monitor.avapritinibrisperidone will increase the level or effect of avapritinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.avapritinib and risperidone both increase sedation. Use Caution/Monitor.axitinibrisperidone increases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.azelastineazelastine and risperidone both increase sedation. Use Caution/Monitor.baclofenbaclofen and risperidone both increase sedation. Use Caution/Monitor.bedaquilinerisperidone and bedaquiline both increase QTc interval. Modify Therapy/Monitor Closely. ECG should be monitored closelybelladonna alkaloidsbelladonna alkaloids decreases levels of risperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.belladonna alkaloids decreases levels of risperidone by pharmacodynamic antagonism. Use Caution/Monitor.risperidone increases effects of belladonna alkaloids by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.belladonna and opiumbelladonna and opium and risperidone both increase sedation. Use Caution/Monitor.belladonna and opium decreases levels of risperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.belladonna and opium decreases levels of risperidone by pharmacodynamic antagonism. Use Caution/Monitor.risperidone increases effects of belladonna and opium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.benazeprilrisperidone, benazepril. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Enhanced hypotensive effects.benperidolbenperidol and risperidone both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.benperidol and risperidone both increase sedation. Use Caution/Monitor.benzhydrocodone/acetaminophenbenzhydrocodone/acetaminophen and risperidone both increase sedation. Use Caution/Monitor.benzphetaminerisperidone increases and benzphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.benztropinerisperidone increases effects of benztropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic adverse effects may be seen with concurrent use. .berotralstatberotralstat will increase the level or effect of risperidone by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Monitor or titrate P-gp substrate dose if coadministered.brexanolonebrexanolone, risperidone. Either increases toxicity of the other by sedation. Use Caution/Monitor.brexpiprazolebrexpiprazole and risperidone both increase sedation. Use Caution/Monitor.brimonidinebrimonidine and risperidone both increase sedation. Use Caution/Monitor.brivaracetambrivaracetam and risperidone both increase sedation. Use Caution/Monitor.brompheniraminebrompheniramine and risperidone both increase sedation. Use Caution/Monitor.buprenorphinebuprenorphine and risperidone both increase sedation. Use Caution/Monitor.buprenorphine buccalbuprenorphine buccal and risperidone both increase sedation. Use Caution/Monitor.buprenorphine subdermal implantbuprenorphine subdermal implant and risperidone both increase sedation. Use Caution/Monitor.buprenorphine transdermalbuprenorphine transdermal and risperidone both increase sedation. Use Caution/Monitor.buprenorphine, long-acting injectionrisperidone increases toxicity of buprenorphine, long-acting injection by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of buprenorphine and benzodiazepines or other CNS depressants increases risk of adverse reactions including overdose, respiratory depression, and death. Cessation of benzodiazepines or other CNS depressants is preferred in most cases. In some cases, monitoring at a higher level of care for tapering CNS depressants may be appropriate. In others, gradually tapering a patient off of a prescribed benzodiazepine or other CNS depressant or decreasing to the lowest effective dose may be appropriate.buprenorphine, long-acting injection and risperidone both increase sedation. Use Caution/Monitor.bupropionbupropion will increase the level or effect of risperidone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.butabarbitalbutabarbital and risperidone both increase sedation. Use Caution/Monitor.butalbitalbutalbital and risperidone both increase sedation. Use Caution/Monitor.butorphanolbutorphanol and risperidone both increase sedation. Use Caution/Monitor.caffeinerisperidone increases and caffeine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.carbamazepinecarbamazepine decreases levels of risperidone by increasing metabolism. Use Caution/Monitor.carbinoxaminecarbinoxamine and risperidone both increase sedation. Use Caution/Monitor.carisoprodolcarisoprodol and risperidone both increase sedation. Use Caution/Monitor.cenobamatecenobamate, risperidone. Either increases effects of the other by sedation. Use Caution/Monitor.chloral hydratechloral hydrate and risperidone both increase sedation. Use Caution/Monitor.chlordiazepoxidechlordiazepoxide and risperidone both increase sedation. Use Caution/Monitor.chloroquinechloroquine increases toxicity of risperidone by QTc interval. Use Caution/Monitor.chlorpheniraminechlorpheniramine and risperidone both increase sedation. Use Caution/Monitor.chlorpromazinechlorpromazine and risperidone both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.chlorpromazine and risperidone both increase QTc interval. Modify Therapy/Monitor Closely.chlorpromazine and risperidone both increase sedation. Use Caution/Monitor.chlorpropamiderisperidone, chlorpropamide. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.chlorzoxazonechlorzoxazone and risperidone both increase sedation. Use Caution/Monitor.cinnarizinecinnarizine and risperidone both increase sedation. Use Caution/Monitor.cisatracuriumcisatracurium decreases levels of risperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.cisatracurium decreases levels of risperidone by pharmacodynamic antagonism. Use Caution/Monitor.risperidone increases effects of cisatracurium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.citalopramcitalopram will increase the level or effect of risperidone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.clarithromycinclarithromycin will increase the level or effect of risperidone by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.clarithromycin and risperidone both increase QTc interval. Modify Therapy/Monitor Closely.clemastineclemastine and risperidone both increase sedation. Use Caution/Monitor.clobazamclobazam will increase the level or effect of risperidone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Lower doses of drugs metabolized by CYP2D6 may be required when used concomitantly. risperidone, clobazam. Other (see comment). Use Caution/Monitor. Comment: Concomitant administration can increase the potential for CNS effects (e.g., increased sedation or respiratory depression).clomipramineclomipramine and risperidone both increase QTc interval. Modify Therapy/Monitor Closely.risperidone and clomipramine both increase sedation. Use Caution/Monitor.clonazepamclonazepam and risperidone both increase sedation. Use Caution/Monitor.clonidineclonidine, risperidone. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium.clorazepateclorazepate and risperidone both increase sedation. Use Caution/Monitor.clotrimazoleclotrimazole will decrease the level or effect of risperidone by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.clozapineclozapine and risperidone both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.clozapine and risperidone both increase sedation. Use Caution/Monitor.clozapine and risperidone both increase QTc interval. Use Caution/Monitor.cobicistatcobicistat will increase the level or effect of risperidone by Other (see comment). Modify Therapy/Monitor Closely. A decrease in the dose of antipsychotics that are metabolized by CYP3A or CYP2D6 may be needed upon coadministration. codeinecodeine and risperidone both increase sedation. Use Caution/Monitor.crizotinibcrizotinib and risperidone both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.cyclizinecyclizine and risperidone both increase sedation. Use Caution/Monitor.cyclizine decreases levels of risperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.cyclizine decreases levels of risperidone by pharmacodynamic antagonism. Use Caution/Monitor.risperidone increases effects of cyclizine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.cyclobenzaprinecyclobenzaprine and risperidone both increase sedation. Use Caution/Monitor.cyclobenzaprine decreases levels of risperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.cyclobenzaprine decreases levels of risperidone by pharmacodynamic antagonism. Use Caution/Monitor.risperidone increases effects of cyclobenzaprine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.cyclosporinecyclosporine will increase the level or effect of risperidone by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.cyproheptadinecyproheptadine and risperidone both increase sedation. Use Caution/Monitor.dantrolenedantrolene and risperidone both increase sedation. Use Caution/Monitor.daridorexantrisperidone and daridorexant both increase sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. darifenacindarifenacin decreases levels of risperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.darifenacin decreases levels of risperidone by pharmacodynamic antagonism. Use Caution/Monitor.risperidone increases effects of darifenacin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.dasatinibdasatinib and risperidone both increase QTc interval. Use Caution/Monitor.desfluranedesflurane and risperidone both increase sedation. Use Caution/Monitor.desipraminedesipramine and risperidone both increase QTc interval. Modify Therapy/Monitor Closely.risperidone and desipramine both increase sedation. Use Caution/Monitor.desvenlafaxinedesvenlafaxine will increase the level or effect of risperidone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Desvenlafaxine inhibits CYP2D6; with higher desvenlafaxine doses (ie, 400 mg) decrease the CYP2D6 substrate dose by up to 50%; no dosage adjustment needed with desvenlafaxine doses <100 mgdeutetrabenazinerisperidone and deutetrabenazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Modify Therapy/Monitor Closely. The risk for parkinsonism, neuroleptic malignant syndrome, and akathisia may be increased by concomitant use of deutetrabenazine and dopamine antagonists or antipsychotics.risperidone and deutetrabenazine both increase sedation. Use Caution/Monitor.deutetrabenazine and risperidone both increase QTc interval. Use Caution/Monitor. At the maximum recommended dose, deutetrabenazine does not prolong QT interval